• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

    8/18/25 9:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care
    Get the next $NTRB alert in real time by email

    ORLANDO, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (the "Company") is pleased to announce that it has been invited to present on the Emerging Growth Conference on August 20, 2025.

    The next Emerging Growth Conference is presenting on August 20, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chairman, Serguei Melnik in real time.

    Mr. Melnik will perform a presentation and may subsequently open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event and Mr. Melnik will do his best to get through as many of them as possible.

    Nutriband Inc. will be presenting at 09:40 AM Eastern time for 30 minutes.

    Please register here to ensure you are able to attend the conference and receive any updates that are released.

    https://goto.webcasts.com/starthere.jsp?ei=1717088&tp_key=22f1f30884&sti=ntrb 

    If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference. We will release a link to that after the event.

    About the Emerging Growth Conference

    The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

    The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

    All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

    About Nutriband Inc.

    We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

    The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

    Forward-Looking Statements

    Certain statements contained in this press release, including, without limitation, statements containing the words "believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K's and Forms 10-Q's, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

    Contact Information:

    Nutriband Inc.

    Phone: 407-377-6695

    Email: [email protected]

    SOURCE: Nutriband Inc.



    Primary Logo

    Get the next $NTRB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NTRB

    DatePrice TargetRatingAnalyst
    1/22/2025$13.00Outperform
    Noble Capital Markets
    More analyst ratings

    $NTRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Noble Capital Markets initiated coverage on Nutriband with a new price target

    Noble Capital Markets initiated coverage of Nutriband with a rating of Outperform and set a new price target of $13.00

    1/22/25 9:24:55 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    SEC Filings

    View All

    Nutriband Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NutriBand Inc. (0001676047) (Filer)

    12/30/25 4:28:50 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    SEC Form DEF 14A filed by Nutriband Inc.

    DEF 14A - NutriBand Inc. (0001676047) (Filer)

    12/19/25 11:01:52 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Nutriband Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NutriBand Inc. (0001676047) (Filer)

    10/28/25 12:00:00 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 5 filed by Sheridan Gareth

    5 - NutriBand Inc. (0001676047) (Issuer)

    11/25/25 5:12:40 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    Goodman Gerald exercised 60,085 in-the-money shares at a strike of $1.93, increasing direct ownership by 1,001% to 66,085 units (SEC Form 5)

    5 - NutriBand Inc. (0001676047) (Issuer)

    10/21/25 1:50:53 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Chief Financial Officer Goodman Gerald

    4 - NutriBand Inc. (0001676047) (Issuer)

    12/2/24 3:49:25 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nutriband CEO Publishes Letter to Shareholders

    ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The full text of the letter is below. Dear Shareholders, As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with us from the beginning and now the many more who have joined our common goal along the way. This goal

    12/31/25 7:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

    Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition The expected closing date for the transaction is Dec 31, 2025. ORLANDO, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), today announced that it has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio. Earthvision Bio has developed and are commercializing a new category of sustainable p

    12/29/25 9:00:00 AM ET
    $INTC
    $NTRB
    Semiconductors
    Technology
    Industrial Specialties
    Health Care

    Nutriband Inc. Signs Letter of Intent with Qvanta Group of Companies to Explore Advanced Technology Solutions for Abuse-Deterrent Pharmaceutical Innovation Strategic Exploration

    ORLANDO, Fla., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company"), a developer of transdermal pharmaceutical products including abuse-deterrent technologies, today announced the signing of a non-binding Letter of Intent ("LOI") with the Qvanta Group of Companies. The Qvanta Group comprises Qvanta LLC and its subsidiaries, Qvanta Foundry LLC and Qvanta Capital LLC (collectively, "Qvanta"). Qvanta is a U.S.-based advanced technology organization developing the BigΔx Quantum Defense Fabric, an integrated quantum-AI cybersecurity and computing platform designed to support enterprise, government, and high-security research environments.

    12/18/25 8:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Nutriband Inc.

    SC 13D/A - NutriBand Inc. (0001676047) (Subject)

    9/19/24 11:38:15 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Nutriband Inc.

    SC 13G - NutriBand Inc. (0001676047) (Subject)

    2/13/24 8:33:52 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Nutriband Inc.

    SC 13G - NutriBand Inc. (0001676047) (Subject)

    2/12/24 3:57:44 PM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    Leadership Updates

    Live Leadership Updates

    View All

    Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

    ORLANDO, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (the "Company") is pleased to announce that it has been invited to present on the Emerging Growth Conference on August 20, 2025. The next Emerging Growth Conference is presenting on August 20, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chairman, Serguei Melnik in real time. Mr. Melnik will perform a presentation and may subsequently open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event and Mr. Melnik will do his best to

    8/18/25 9:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors

    The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placementORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.Mr. Glinka, an Estonian citizen, is an experienced and highly regarded businessman who has held numerous Executive and Board positions in large European Companies providing Glinka with deep insights and networks across various industri

    5/16/24 7:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    $NTRB
    Financials

    Live finance-specific insights

    View All

    Nutriband CEO Publishes Letter to Shareholders

    ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The full text of the letter is below. Dear Shareholders, As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with us from the beginning and now the many more who have joined our common goal along the way. This goal

    12/31/25 7:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Nutriband Confirms Record and Pay date for 25% Preferred Stock Dividend as it Targets Filing for FDA Approval

    ORLANDO, Fla., July 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") is today reminding shareholders of the key dates associated with its upcoming 25% Preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August. 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company's AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an ann

    7/18/25 9:15:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Nutriband Announces 25% Preferred Stock Dividend as it targets filing for FDA approval

    ORLANDO, Fla., July 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) ("Nutriband" or the "Company") announced today that its Board of Directors has approved and declared a 25% preferred stock dividend. Shareholders of record on July 25th 2025 will receive one preferred share for every four shares of common stock held. The pay date for shareholders to receive their new issuance will be August 5th. Each preferred share will be convertible to one share of common stock following FDA approval of the Company's AVERSA Fentanyl product. If the preferred share remains unconverted it shall be entitled to a cash dividend paid from the profits of the company on an annual bas

    7/2/25 8:05:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care